The diagnosis of an insulin-secreting islet cell adenoma was obscured in a patient treated with diphenylhydantoin sodium. Comparison of insulin responses to glucagon, tolbutamide, and leucine before and after drug withdrawal indicated that the diphenylhydantoin was inhibiting "stimulated" insulin release from the tumor.Another clue to hyperinsulinism was the restraint of hepatic ketogenesis and urinary nitrogen excretion during fasting. Diphenylhydantoin, or an analogue, may deserve further trial as adjunctive therapy in the control of insulinoma-induced hypoglycemia.The hyperglycémie potential of diphenylhydantoin sodium was first recognized by Belton et al in 1965.1 Since then, hyperglycemic-hyperosmolar coma has been associated repeatedly with diphenylhydantoin intoxication.2'7 In one case, intoler¬ ance to orally given glucose was in¬ duced by conventional doses of di¬ phenylhydantoin.8 It is believed that diphenylhydantoin causes hyperglycemia by inhibiting insulin release from the pancreas.7-9·10·11 In this light, the effect of diphenylhydantoin ther¬ apy on insulin secretion from an islet cell tumor is potentially important and is the basis for this report.
Patient SummaryHistory.-A 44-year-old auto mechanic had been suffering grand mal seizures from childhood onward. In 1950, he was first seen at Northwestern University Medical Clinics for seizures. These had oc¬ curred several times yearly, sometimes be¬ ginning in the left arm and face, but al¬ ways progressing to generalized, tonicclonic activity followed by brief periods of unconsciousness and two to three hours of postictal drowsiness. Seizures would com¬ monly occur during sleep or after alcohol intake, but also while awake and, on one occasion, while driving. A maternal uncle had seizures; there was no other family history of epilepsy or diabetes. Physical examination disclosed no neurological abnormality. Medications consisted of di-